SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhang, Tao ^a   Rong, Ningning ^b   Chen, Juan ^c   Zou, Chengwei ^a   Jing, Haiyan ^a   Zhu, Xiaolong ^a   Zhang, Wenlong ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^c Jinan Second People's Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; SIRTUIN 1; SMALL INTERFERING RNA;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CELL INVASION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; MIGRATION INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TUMOR DIFFERENTIATION; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CISPLATIN; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; SIRTUIN 1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892405563     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079162     Document Type: Article

References (41)

1. Subramaniam S, Thakur RK, Yadav VK, Nanda R, Chowdhury S et al. (2013) Lung cancer biomarkers: State of the art. J Carcinog 12: 3. doi:10.4103/1477- 3163.107958. PubMed: 23599685.
2. Tsim S, O'Dowd CA, Milroy R, Davidson S (2010) Staging of non-small cell lung cancer (NSCLC): a review. Respir Med 104: 1767-1774. doi:10.1016/j.rmed. 2010.08.005. PubMed: 20833010.
3. Kosmidis P (2002) Chemotherapy in NSCLC: historical review. Lung Cancer 38 Suppl 3: S19-S22. doi:10.1016/S0169-5002(02)00261-1. PubMed: 12468139.
4. Hildebrandt MA, Gu J, Wu X (2009) Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5: 745-755. doi:10.1517/17425250902973711. PubMed: 19442035.
5. Gridelli C, Ferrara C, Del Gaizo F, Guerriero C, Nicolella D et al. (2002) Chemotherapy of advanced NSCLC in the elderly. Tumori 88: S143- S144. PubMed: 11989910.
6. Stuschke M, Pöttgen C (2010) Chemotherapy: Effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol 7: 613-614. doi:10.1038/nrclinonc.2010.165. PubMed: 20981122.
7. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD (2008) Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer 122: 1810-1819. PubMed: 18074354.
8. Sauve AA, Wolberger C, Schramm VL, Boeke JD (2006) The biochemistry of sirtuins. Annu Rev Biochem 75: 435-465. doi:10.1146/annurev.biochem.74.082803. 133500. PubMed: 16756498.
9. Fusco S, Maulucci G, Pani G (2012) Sirt1: def-eating senescence? Cell Cycle 11: 4135-4146. doi:10.4161/cc.22074. PubMed: 22983125.
10. Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI et al. (2012) SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLOS ONE 7: e45119. doi:10.1371/journal.pone.0045119. PubMed: 23024800.
11. Chen W, Bhatia R (2013) Roles of SIRT1 in leukemogenesis. Curr Opin Hematol, 20: 308-13. PubMed: 23519155.
12. Li X (2013) SIRT1 and energy metabolism. Acta Biochim Biophys Sin (Shanghai) 45: 51-60. doi:10.1093/abbs/gms108.
13. Lee H, Kim KR, Noh SJ, Park HS, Kwon KS et al. (2011) Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42: 204-213. doi:10.1016/j.humpath.2010.05.023. PubMed: 21056897.
14. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA et al. (2007) SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618. doi:10.1158/0008-5472.CAN-07-0085. PubMed: 17638871.
15. Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T et al. (2012) SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 27: 1726-1732. PubMed: 22470132.
16. Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW et al. (2012) DBC1 does not function as a negative regulator of SIRT1 in liver cancer. Oncol Lett 4: 873-877. PubMed: 23162614.
17. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K et al. (2006) Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 25: 176-185. PubMed: 16170353.
18. Sun Y, Sun D, Li F, Tian L, Li C et al. (2007) Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 58: 21-29. doi:10.1016/j.lungcan.2007.05.013. PubMed: 17624472.
19. Chen HC, Jeng YM, Yuan RH, Hsu HC, Chen YL (2012) SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis. Ann Surg Oncol 19: 2011-2019. doi:10.1245/s10434-011-2159-4. PubMed: 22146883.
20. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA et al. (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714. doi:10.1097/JTO.0b013e31812f3c1a. PubMed: 17762336.
21. Wu F, Hu N, Li Y, Bian B, Xu G et al. (2012) Galectin-3 genetic variants are associated with platinum-based chemotherapy response and prognosis in patients with NSCLC. Cell Oncol (Dordr) 35: 175-180.
22. Remmele W, Stegner HE (1987) [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8: 138-140. PubMed: 3303008.
23. Zhou C, Liu G, Wang L, Lu Y, Yuan L et al. (2013) MiR-339-5p Regulates the Growth, Colony Formation and Metastasis of Colorectal Cancer Cells by Targeting PRL-1. PLOS ONE 8: e63142. doi:10.1371/journal.pone.0063142. PubMed: 23696794.
24. Dai C, Zhang B, Liu X, Ma S, Yang Y et al. (2013) Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice. Endocrinology 154: 1247-1259. doi:10.1210/en.2012-1908. PubMed: 23384836.
25. Sundaresan NR, Pillai VB, Gupta MP (2011) Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J Mol Cell Cardiol 51: 614-618. doi:10.1016/j.yjmcc.2011.01.008. PubMed: 21276800.
26. Kong S, McBurney MW, Fang D (2012) Sirtuin 1 in immune regulation and autoimmunity. Immunol Cell Biol 90: 6-13. doi:10.1038/icb.2011.102. PubMed: 22105513.
27. Metoyer CF, Pruitt K (2008) The role of sirtuin proteins in obesity. Pathophysiology 15: 103-108. doi:10.1016/j.pathophys.2008.04.002. PubMed: 18599274.
28. Mantel C, Broxmeyer HE (2008) Sirtuin 1, stem cells, aging, and stem cell aging. Curr Opin Hematol 15: 326-331. doi:10.1097/MOH. 0b013e3283043819. PubMed: 18536570.
29. Zschoernig B, Mahlknecht U (2008) SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun 376: 251-255. doi:10.1016/j.bbrc.2008.08.137. PubMed: 18774777.
30. Oppenheimer H, Gabay O, Meir H, Haze A, Kandel L et al. (2012) 75-kd sirtuin 1 blocks tumor necrosis factor alpha-mediated apoptosis in human osteoarthritic chondrocytes. Arthritis Rheum 64: 718-728. doi:10.1002/art.33407. PubMed: 21987377.
31. Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M et al. (2012) High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer 131: 2044-2055. doi:10.1002/ijc.27481. PubMed: 22322739.
32. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S et al. (2008) The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLOS ONE 3: e2020. doi:10.1371/journal.pone.0002020. PubMed: 18414679.
33. Wu M, Wei W, Xiao X, Guo J, Xie X et al. (2012) Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. Med Oncol 29: 3240-3249. doi:10.1007/s12032-012-0260-6. PubMed: 22661383.
34. Wang RH, Sengupta K, Li C, Kim HS, Cao L et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323. doi:10.1016/j.ccr.2008.09.001. PubMed: 18835033.
35. Fu M, Liu M, Sauve AA, Jiao X, Zhang X et al. (2006) Hormonal control of androgen receptor function through SIRT1. Mol Cell Biol 26: 8122-8135. doi:10.1128/MCB.00289-06. PubMed: 16923962.
36. Xie Y, Zhang J, Xu Y, Shao C (2012) SirT1 confers hypoxia-induced radioresistance via the modulation of c-Myc stabilization on hepatoma cells. J Radiat Res 53: 44-50. doi:10.1269/jrr.11062. PubMed: 22302044.
37. Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C et al. (2009) Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 380: 236-242. doi:10.1016/j.bbrc.2009.01.040. PubMed: 19166820.
38. Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M et al. (2005) Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 10: 321-332. doi:10.1111/j.1365-2443.2005.00836.x. PubMed: 15773895.
39. Brooks CL, Gu W (2009) Anti-aging protein SIRT1: a role in cervical cancer? Aging (Albany NY) 1: 278-280. PubMed: 20157516.
40. Brooks CL, Gu W (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9: 123-128. doi:10.1038/nrc2562. PubMed: 19132007.
41. Lovaas JD, Zhu L, Chiao CY, Byles V, Faller DV et al. (2013) SIRT1 enhances matrix metalloproteinase-2 expression and tumor cell invasion in prostate cancer cells. Prostate 73: 522-530. doi:10.1002/pros.22592. PubMed: 23038275.